BioTuesdays

Tag - BTIG

CymaBay-Logo

BTIG starts CymaBay at buy; PT $15

BTIG launched coverage of CymaBay Therapeutics (NASDAQ:CBAY) with a “buy” rating and $15 price target. The stock closed at $9.11 on March 8. Analyst Julian Harrison writes that the company’s seladelpar is well...

MoonLake Logo

BTIG starts Moonlake at buy; PT $36

BTIG initiated coverage of Moonlake Immunotherapeutics (NASDAQ:MLTX) with a “buy” rating and $36 price target. The stock closed at $23.70 on March 8. “We see Moonlake’s sonelokimab (SLK) well-positioned to emerge as the...

BTIG starts Sophia Genetics at buy; PT $6

BTIG initiated coverage of Sophia Genetics (NASDAQ:SOPH) with a “buy” rating and $6 price target. The stock price closed at $2.06 on Dec. 30. Sophia is a rapidly growing, global healthcare technology company that sells...

Aerovate Therapeutics

BTIG ups Aerovate to buy on competitor data

BTIG upgraded Aerovate Therapeutics (NASDAQ:AVTE) to “buy” from “neutral” with a $27 price target, citing Gossamer Bio’s TORREY results that could validate Aerovate’s dry powder inhalation (DPI) administered tyrosine...

Cullinan Logo

BTIG starts Cullinan Oncology at buy; PT $20

BTIG initiated coverage of Cullinan Oncology (NASDAQ:CGEM) with a “buy” rating and price target of $20, citing a burgeoning pipeline and unique biology that could open avenues for a broad range of opportunities. The...

Annexon Logo

BTIG starts Annexon at buy; PT $15

BTIG initiated coverage of Annexon (NASDAQ:ANNX) with a “buy” rating and $15 price target. The stock closed at $6.02 on Sept. 8. Annexon, Inc. is a development-stage biotech company focused on mediating the role of...

Pear Therapeutics

BTIG cuts Pear Therapeutics PT to $5 on Q2 results

BTIG reduced its price target for Pear Therapeutics (NASDAQ:PEAR) to $5 from $11 but maintained its “buy” rating after the company missed second quarter revenue consensus and lowered 2022 revenue guidance. The stock...